The new drug of ibuprofen and hepatitis C, obipali tablets + dasebwey sodium tablets, officially launched in the Chinese market

Source: Medical magic cube data 2018-01-08 On January 6, eberver announced that its direct antiviral treatment program for the treatment of adult genotype 1 chronic hepatitis C - obipalin tablets combined with dacebwei sodium tablets officially landed in the Chinese market Patients in Shanghai, Beijing and Zhejiang have benefited from this innovative treatment program, and are expected to completely bid farewell to hepatitis C and usher in a "beautiful new world" through a 12 week course of treatment According to the data of two phase 3 clinical studies on Asian chronic hepatitis C patients with genotype 1b, including three kinds of direct antiviral drugs, from the three main targets of the life cycle of hepatitis C virus, to inhibit the replication of hepatitis C virus, the so-called "3D scheme" of the combination of ibovebiapril tablets and dasebuvir sodium tablets treatment scheme is all oral, interferon free, combinable or unconjugated ribavir Lin, used for the treatment of adult genotype 1 chronic hepatitis C, including patients without cirrhosis or with compensatory cirrhosis, the course of treatment can be as short as 12 weeks, and the sustained virological response rate (svr12) is 99.5% - 100% In addition, the efficacy of this program is not affected by the baseline drug resistance of NS5A, and it is not necessary to detect the baseline drug resistance before use Based on the excellent performance of the phase III clinical data of obipali + dasebovir treatment scheme, Professor Wang GuiQiang, director of the Department of infectious diseases and director of the liver disease center of the first hospital of Peking University, said, "from the perspective of genotyping, the proportion of hepatitis C patients in China with genotype 1b is the largest, accounting for about 56.8% The obipali + dasebovir regimen has a stable high cure rate and safety for patients with genotype 1b " At present, the combination of obipalin tablets and dasebovir sodium tablets has been approved in more than 70 countries and regions around the world for clinical treatment of patients with genotype 1 chronic hepatitis C, including the United States and all 28 EU Member States This program has been recommended as an effective treatment option for hepatitis C patients by several guidelines issued by EASL, AASLD and IDSA In the United States, the program has been recognized by the U.S Food and Drug Administration (FDA) as a priority review qualification and breakthrough therapy In China, the program has also been awarded the priority evaluation qualification by the drug evaluation center (CDE) of China food and Drug Administration (CFDA) "Obipali tablets and dacebuvir sodium tablets were officially launched in China, once again showing the world an amazing 'Chinese speed' From March 2017, when the treatment scheme was applied for listing in China to be approved, it only took 6.5 months, during which it was given priority review for three times, and from being approved to being officially launched, it only took two months." "We are very happy to provide innovative and efficient treatment programs for hepatitis C patients in China, to help patients achieve early cure," said O Silang, general manager of Albright China "We will not let any patient become an exception to hepatitis C cure." "Recently, several direct anti viral (DAA) drugs for hepatitis C have been approved for marketing, marking a new era of hepatitis C treatment in China." Professor Zhuang Hui, academician of Chinese Academy of engineering and honorary chairman of Hepatology branch of Chinese Medical Association, said, "Albright's obipali tablets and dasebway sodium tablets can be used not only for patients without cirrhosis and hepatitis C, but also for patients with compensatory cirrhosis and hepatitis C, as well as patients with liver and kidney dysfunction, which is conducive to more patients with hepatitis C receiving DAA treatment From the existing global data, the real world efficacy data of DAA is basically consistent with the clinical research data, and the sustained virological response rate is very high, which indicates that DAA has a good effect on the treatment of hepatitis C It is hoped that such innovative drugs can be incorporated into the national health insurance catalogue as soon as possible, so that more hepatitis C patients can receive DAA treatment, and realize the great goal of "eliminating the serious public health threat of viral hepatitis by 2030" as soon as possible It is reported that hepatitis C is a global public health problem and a major threat that coexists with HIV, tuberculosis and malaria The global hepatitis C infection rate is 1%, about 71 million people There are about 10 million people infected with hepatitis C virus in China, which is one of the countries with the largest number of people infected with hepatitis C in the world If China is to realize the serious public health threat of who "eliminating viral hepatitis by 2030", only in the field of hepatitis C, China needs to treat at least 550000 patients every year It is understood that another heavy-duty pan gene product of hepatitis C has been approved and launched in the United States, the European Union and Japan, and can be cured in 8 weeks! In the future, Aberdeen will promote the marketing process of this epoch-making innovative drug in China "Albright has always been committed to providing innovative and effective treatment programs for as many Chinese hepatitis C patients as possible, and contributing to the realization of eliminating the serious public health threat of viral hepatitis by 2030," said ou Silang, general manager of Albright China We look forward to continuing to be a reliable partner, actively promoting multi-party cooperation, and jointly promoting China's early entry into a "hepatitis C free society."